Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.88 Average Target Price from Brokerages

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $18.8750.

Several equities research analysts recently commented on LXEO shares. Chardan Capital reiterated a “buy” rating and issued a $17.00 price objective on shares of Lexeo Therapeutics in a report on Tuesday, January 13th. Raymond James Financial started coverage on Lexeo Therapeutics in a report on Wednesday, December 17th. They issued a “strong-buy” rating and a $25.00 price objective for the company. Finally, HC Wainwright reduced their price objective on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th.

Lexeo Therapeutics Price Performance

Lexeo Therapeutics stock opened at $6.38 on Tuesday. Lexeo Therapeutics has a one year low of $1.97 and a one year high of $10.99. The business’s fifty day moving average is $6.43 and its 200 day moving average is $7.99. The stock has a market capitalization of $472.68 million, a PE ratio of -2.91 and a beta of 1.99.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 30th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.05. As a group, sell-side analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the sale, the chief executive officer directly owned 340,106 shares in the company, valued at approximately $1,935,203.14. This trade represents a 13.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 68,189 shares of company stock valued at $397,156. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. RA Capital Management L.P. purchased a new position in Lexeo Therapeutics in the fourth quarter worth about $49,650,000. Paradigm Biocapital Advisors LP purchased a new position in Lexeo Therapeutics in the fourth quarter worth about $47,299,000. Vestal Point Capital LP boosted its position in Lexeo Therapeutics by 37.7% in the fourth quarter. Vestal Point Capital LP now owns 4,475,000 shares of the company’s stock worth $44,437,000 after purchasing an additional 1,225,000 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its position in Lexeo Therapeutics by 363.1% in the second quarter. Frazier Life Sciences Management L.P. now owns 4,424,725 shares of the company’s stock worth $17,787,000 after purchasing an additional 3,469,210 shares during the last quarter. Finally, Balyasny Asset Management L.P. purchased a new position in Lexeo Therapeutics in the second quarter worth about $16,117,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.